AU2018237123B2 - Bruton's tyrosine kinase inhibitors - Google Patents

Bruton's tyrosine kinase inhibitors Download PDF

Info

Publication number
AU2018237123B2
AU2018237123B2 AU2018237123A AU2018237123A AU2018237123B2 AU 2018237123 B2 AU2018237123 B2 AU 2018237123B2 AU 2018237123 A AU2018237123 A AU 2018237123A AU 2018237123 A AU2018237123 A AU 2018237123A AU 2018237123 B2 AU2018237123 B2 AU 2018237123B2
Authority
AU
Australia
Prior art keywords
pyrazin
phenyl
imidazo
pyrrolidin
methoxyphenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018237123A
Other languages
English (en)
Other versions
AU2018237123A1 (en
Inventor
Anhui GAO
Jia Li
Xibin Liao
Zhijian Lu
Yubo ZHOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Baijibugong Pharmaceutical Technology Co Ltd
Original Assignee
Suzhou Baijibugong Pharmaceutical Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Baijibugong Pharmaceutical Tech Co Ltd filed Critical Suzhou Baijibugong Pharmaceutical Tech Co Ltd
Publication of AU2018237123A1 publication Critical patent/AU2018237123A1/en
Application granted granted Critical
Publication of AU2018237123B2 publication Critical patent/AU2018237123B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2018237123A 2017-03-22 2018-03-21 Bruton's tyrosine kinase inhibitors Active AU2018237123B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762474686P 2017-03-22 2017-03-22
US62/474,686 2017-03-22
PCT/US2018/023455 WO2018175512A1 (en) 2017-03-22 2018-03-21 Bruton's tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2018237123A1 AU2018237123A1 (en) 2019-10-10
AU2018237123B2 true AU2018237123B2 (en) 2022-08-04

Family

ID=63585694

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018237123A Active AU2018237123B2 (en) 2017-03-22 2018-03-21 Bruton's tyrosine kinase inhibitors

Country Status (12)

Country Link
US (3) US11554118B2 (enExample)
EP (1) EP3601264A4 (enExample)
JP (1) JP7219902B2 (enExample)
KR (1) KR102627756B1 (enExample)
CN (1) CN110494433B (enExample)
AU (1) AU2018237123B2 (enExample)
CA (1) CA3055602A1 (enExample)
EA (1) EA201992147A1 (enExample)
IL (1) IL269152B2 (enExample)
MX (1) MX2019011116A (enExample)
WO (1) WO2018175512A1 (enExample)
ZA (1) ZA201906887B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7219902B2 (ja) * 2017-03-22 2023-02-09 スジョウ・バイジブゴン・ファーマスーティカル・テクノロジー・カンパニー・リミテッド ブルトン型チロシンキナーゼ阻害剤
JP2022517280A (ja) * 2019-01-18 2022-03-07 シービン リィアォ ブルトン型チロシンキナーゼ阻害剤
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CN111909133B (zh) * 2019-05-10 2023-07-14 河南知微生物医药有限公司 作为布鲁诺酪氨酸激酶抑制剂的取代的1-氨基-1h-咪唑-5-甲酰胺
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN111471048B (zh) * 2020-04-30 2021-06-15 成都海博为药业有限公司 一种具有含氮桥环、螺环或并环结构的化合物及其用途
CN115073468B (zh) * 2021-03-15 2023-12-22 药雅科技(上海)有限公司 咪唑并吡嗪类btk抑制剂的制备及用途
WO2022228302A1 (en) * 2021-04-25 2022-11-03 Bionova Pharmaceuticals (Shanghai) Limited Heteroaromatic carboxamide compounds and its use

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058755A2 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of imidazo[1,5-a]pyridin-3-yl derivatives and related heterobicycles for targetting compounds capable of binding to g-protein coupled receptors
WO2008022060A2 (en) * 2006-08-14 2008-02-21 Novartis Ag Imidazo-pyridine derivatives for modulating protein kinase activity
WO2011095556A1 (en) * 2010-02-08 2011-08-11 N.V. Organon 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds
WO2013010869A1 (en) * 2011-07-19 2013-01-24 Msd Oss B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors
WO2013102860A1 (en) * 2012-01-04 2013-07-11 Sanofi Therapeutic use of imidazopyridine derivatives
WO2015025025A1 (en) * 2013-08-22 2015-02-26 F. Hoffmann-La Roche Ag Alkynyl alcohols and methods of use
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
WO2016106626A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
WO2017156495A1 (en) * 2016-03-11 2017-09-14 Corvus Pharmaceuticals, Inc. Compounds and methods for modulating bruton's tyrosine kinase

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004268918A1 (en) * 2003-09-03 2005-03-10 Galapagos Nv Imidazo(1,5-a)pyridine or imidazo(1,5-a)piperidine derivatives and their use for the preparation of medicament against 5-HT2A receptor-related disorders
PT2201840E (pt) 2006-09-22 2012-02-14 Pharmacyclics Inc Inibidores da tirosina quinase de bruton
EA017865B1 (ru) 2007-03-28 2013-03-29 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
US20140221354A1 (en) 2011-03-31 2014-08-07 Emblem Technology Transfer Gmbh IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY
GB2513821A (en) * 2011-06-28 2014-11-12 Andrew Levine Speech-to-text conversion
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
JP5826931B2 (ja) 2011-07-19 2015-12-02 メルク・シャープ・エンド・ドーム・ベー・フェー Ｂｔｋ阻害剤としての４−イミダゾピリダジン−１−イル−ベンズアミドおよび４−イミダゾトリアジン−１−イル−ベンズアミド
CA2863239C (en) * 2012-01-31 2016-09-13 Beta Pharma Canada Inc. Cyclic molecules as bruton's tyrosine kinase inhibitors
WO2014113942A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
US20140206681A1 (en) 2013-01-23 2014-07-24 Ronald M. Kim Btk inhibitors
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
WO2016106623A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Benzamide imidazopyrazine btk inhibitors
WO2016106652A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Biarylether imidazopyrazine btk inhibitors
MA41614A (fr) * 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
MA42242A (fr) * 2015-06-24 2018-05-02 Principia Biopharma Inc Inhibiteurs de la tyrosine kinase
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
CN106478633A (zh) 2015-08-27 2017-03-08 正大天晴药业集团股份有限公司 一类布鲁顿酪氨酸激酶抑制剂
US20170071962A1 (en) * 2015-09-11 2017-03-16 Acerta Pharma B.V. Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor
US20170035881A1 (en) 2015-10-19 2017-02-09 Acerta Pharma B.V. Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor
US10736893B2 (en) * 2015-11-06 2020-08-11 Acerta Pharma B.V. Imidazopyrazine inhibitors of Bruton's tyrosine kinase
US10640512B2 (en) 2016-06-30 2020-05-05 Hangzhou Sanyintai Pharmaceutical Technology Co., Ltd. Imidazopyrazinamine phenyl derivative and use thereof
CN109851620B (zh) 2016-08-17 2020-08-07 深圳市塔吉瑞生物医药有限公司 用于抑制酪氨酸激酶活性的稠合双环类化合物
JP7219902B2 (ja) * 2017-03-22 2023-02-09 スジョウ・バイジブゴン・ファーマスーティカル・テクノロジー・カンパニー・リミテッド ブルトン型チロシンキナーゼ阻害剤

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058755A2 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of imidazo[1,5-a]pyridin-3-yl derivatives and related heterobicycles for targetting compounds capable of binding to g-protein coupled receptors
WO2008022060A2 (en) * 2006-08-14 2008-02-21 Novartis Ag Imidazo-pyridine derivatives for modulating protein kinase activity
WO2011095556A1 (en) * 2010-02-08 2011-08-11 N.V. Organon 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds
WO2013010869A1 (en) * 2011-07-19 2013-01-24 Msd Oss B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors
WO2013102860A1 (en) * 2012-01-04 2013-07-11 Sanofi Therapeutic use of imidazopyridine derivatives
WO2015025025A1 (en) * 2013-08-22 2015-02-26 F. Hoffmann-La Roche Ag Alkynyl alcohols and methods of use
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
WO2016106626A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
WO2017156495A1 (en) * 2016-03-11 2017-09-14 Corvus Pharmaceuticals, Inc. Compounds and methods for modulating bruton's tyrosine kinase

Also Published As

Publication number Publication date
WO2018175512A1 (en) 2018-09-27
IL269152B2 (en) 2023-11-01
EA201992147A1 (ru) 2020-02-20
AU2018237123A1 (en) 2019-10-10
IL269152A (en) 2019-11-28
MX2019011116A (es) 2020-02-05
US20210121458A1 (en) 2021-04-29
JP7219902B2 (ja) 2023-02-09
CN110494433A (zh) 2019-11-22
EP3601264A4 (en) 2021-03-24
BR112019019588A2 (pt) 2020-04-22
US11554118B2 (en) 2023-01-17
KR102627756B1 (ko) 2024-01-23
JP2020511547A (ja) 2020-04-16
EP3601264A1 (en) 2020-02-05
CN110494433B (zh) 2023-03-17
US20190275037A1 (en) 2019-09-12
ZA201906887B (en) 2022-03-30
CA3055602A1 (en) 2018-09-27
IL269152B1 (en) 2023-07-01
US10933063B2 (en) 2021-03-02
US11974999B2 (en) 2024-05-07
US20210107903A1 (en) 2021-04-15
KR20190133199A (ko) 2019-12-02

Similar Documents

Publication Publication Date Title
AU2018237123B2 (en) Bruton's tyrosine kinase inhibitors
AU2017208998B2 (en) Bruton's tyrosine kinase inhibitors
WO2017066014A1 (en) Bruton's tyrosine kinase inhibitors
AU2013272701A1 (en) Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
CN116813647B (zh) 一类含氮稠环类sting调节剂类化合物、制备方法和用途
KR20160086930A (ko) 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도
AU2019295983B2 (en) Tricyclic compounds
KR20210108433A (ko) 티에노피리디논 화합물
KR20240150419A (ko) 아릴설폰아미드 화합물
ES2771151T3 (es) Derivados de piperidina como inhibidor de señalización wnt
BR112019019588B1 (pt) Composto e composição farmacêutica
EA042551B1 (ru) Ингибиторы тирозинкиназы брутона
CN119707930A (zh) 芳香环类化合物及其制法和用途
BR112018014705B1 (pt) Compostos inibidores de tirosina quinase de Bruton e composição farmacêutica
NZ711699A (en) P2x7 modulators
NZ711699B2 (en) P2x7 modulators

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)